Download PDF (external access)

New England Journal of Medicine

Publication date: 2013-01-01
Volume: 368 Pages: 138 - 48
Publisher: Massachusetts Medical Society

Author:

Ryan, Charles J
Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter FA ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E ; COU-AA-302 Investigators,

Keywords:

Androstadienes, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Humans, Male, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Survival Analysis, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, HUMAN CYTOCHROME P450(17-ALPHA), HORMONAL-THERAPY, CONTROLLED-TRIAL, END-POINTS, ACETATE, MITOXANTRONE, INHIBITION, PREDNISONE, DOCETAXEL, CYP17, Abiraterone Acetate, COU-AA-302 Investigators, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.